PT  - JOURNAL ARTICLE
AU  - Reingruber, Jürgen
AU  - Papale, Andrea
AU  - Holcman, David
TI  - Monitoring and predicting SARS-CoV-2 epidemic in France after deconfinement using a multiscale and age-dependent model
AID  - 10.1101/2020.05.15.20099465
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.15.20099465
4099  - http://medrxiv.org/content/early/2020/05/23/2020.05.15.20099465.short
4100  - http://medrxiv.org/content/early/2020/05/23/2020.05.15.20099465.full
AB  - The world and France were strongly impacted by the SARS-COV-2 epidemic. Finding appropriate measures that effectively contain the epidemic without putting severe pressure on social and economic life is a major challenge for modern predictive approaches. We developed an analytical framework to precisely monitor and predict the spread of the epidemic together with its impact on the health care system. The current implementation accounts for interactions between five age-stratified population groups, and predicts disease progression and hospitalization status using eight different categories such as infected, hospitalized, occupancy of intensive care units, deceased, recovered from hospitalization and more. We use a variety of public health care data for the five most infected regions of France during lockdown (March 18th till May 11th) to validate and calibrate the model. At day of deconfinement (May 11th), we find that around 14% (around 4.8M) of the population is infected in the five most affected regions of France (extrapolating to 5.8M for France). We then apply the calibrated model to explore different deconfinement scenarios. We find that wearing of masks and social distancing can prevent a significant second peak. In the context of school openings with limited testing capacities, we argue that testing should focus on children, but without tracing it will have only a limited impact. Finally, we explore a complementary deconfinement scenario where the fragile elderly population initially remains confined, while the rest of the population becomes gradually deconfined to achieve herd immunity within few month before deconfining also the elderly.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yespublic data available online (see url below) https://www.data.gouv.fr/fr/datasets/donnees-hospitalieres-relatives-a-lepidemie-de-covid-19/ https://geodes.santepubliquefrance.fr/\#c=news